AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 793848 — intervention group
Group type: COMPARATOR
Intervention: Alpha-methyldopa
Number of subjects: 37
Study 793848 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 37
Study 30222489 — intervention group
Group type: EXPERIMENTAL
Intervention: SUREE without visual feedback
Number of subjects: 42
Study 30222489 — intervention group
Group type: EXPERIMENTAL
Intervention: SUREE with visual feedback
Number of subjects: 42
Study 30222489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 29236887 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates (n = 22)
Number of subjects: 63
Study 29236887 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (n = 21)
Number of subjects: 63
Study 29236887 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 20)
Number of subjects: 63
Study 25533998 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ramelteon
Number of subjects: 17
Study 25533998 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg triazolam
Number of subjects: 17
Study 25533998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 23727256 — intervention group
Group type: EXPERIMENTAL
Intervention: Small plate size (19.5 cm)
Number of subjects: 20
Study 23727256 — intervention group
Group type: COMPARATOR
Intervention: Large plate size (26.5 cm)
Number of subjects: 20
Study 21838410 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (after starting dose of 30 mg QD for 1 week)
Number of subjects: 527
Study 21838410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 527
Study 19647467 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular human insulin, administered twice a day for 36 months
Number of subjects: 50
Study 19647467 — intervention group
Group type: COMPARATOR
Intervention: Observation/control group
Number of subjects: 50
Study 19647467 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular human insulin
Number of subjects: 50
Study 16762534 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 1082
Study 16762534 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Number of subjects: 1082
Study 14725953 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report service utilization
Number of subjects: 0
Study 14725953 — intervention group
Group type: COMPARATOR
Intervention: Agency records of service utilization
Number of subjects: 0
Study 11497193 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with LVH by both Cornell product and Sokolow‐Lyon criteria (n=106)
Number of subjects: 906
Study 11497193 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ECG LVH by Cornell product criteria (n=410)
Number of subjects: 906
Study 11497193 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ECG LVH by Sokolow‐Lyon voltage criteria (n=162)
Number of subjects: 906
Study 11497193 — intervention group
Group type: COMPARATOR
Intervention: Patients with only Sokolow‐Lyon voltage criteria
Number of subjects: 906
Study 11497193 — intervention group
Group type: COMPARATOR
Intervention: Patients with only Cornell product criteria
Number of subjects: 906
Study 11497193 — intervention group
Group type: COMPARATOR
Intervention: Patients with both ECG criteria
Number of subjects: 906
Study 9806254 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg triptorelin acetate s.c. daily
Number of subjects: 48
Study 9806254 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg triptorelin acetate s.c. daily
Number of subjects: 48
Study 9806254 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg triptorelin acetate s.c. daily
Number of subjects: 48
Study 9806254 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg triptorelin acetate s.c. daily
Number of subjects: 48
Study 7706149 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist-based training
Number of subjects: 48
Study 7706149 — intervention group
Group type: COMPARATOR
Intervention: Professionally developed films
Number of subjects: 48
Study 2506263 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 14
Study 2506263 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 14
Study 2506263 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 14
Study 2506263 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (180 mg)
Number of subjects: 14
Study 871198 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml 4% lignocaine spray
Number of subjects: 0
Study 871198 — intervention group
Group type: COMPARATOR
Intervention: 0-9% saline (control)
Number of subjects: 0
Study 30267738 — intervention group
Group type: EXPERIMENTAL
Intervention: RNase1 treatment (pre-treated with RNase1 24 hours before A. hydrophila injection)
Number of subjects: 4
Study 30267738 — intervention group
Group type: COMPARATOR
Intervention: Control group (injected PBS)
Number of subjects: 4
Study 30267738 — intervention group
Group type: COMPARATOR
Intervention: Challenge group (A. hydrophila-injected)
Number of subjects: 4
Study 30267738 — intervention group
Group type: COMPARATOR
Intervention: Blank group (none-treated M. amblycephala)
Number of subjects: 4
Study 28103255 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated school uniforms
Number of subjects: 1811
Study 28103255 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 1811
Study 25500425 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 10 mg, 25 mg, or 50 mg once daily for 3 months
Number of subjects: 165
Study 25500425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 25500425 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA)
Number of subjects: 165
Study 23876672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial behavior physical activity (PBPA) intervention, which includes structured physical activity sessions, cognitive-behavioral counseling, and opportunities to earn food for donation based on physical activity and volunteering.
Number of subjects: 300
Study 23876672 — intervention group
Group type: COMPARATOR
Intervention: Healthy aging (HA) control intervention, based on educational sessions.
Number of subjects: 300
Study 23876672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial behavior physical activity (PBPA) intervention
Number of subjects: 300
Study 23876672 — intervention group
Group type: COMPARATOR
Intervention: Healthy aging (HA) control intervention
Number of subjects: 300
Study 21975193 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) plus treatment as usual (TAU)
Number of subjects: 27
Study 21975193 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 27
Study 19291747 — intervention group
Group type: EXPERIMENTAL
Intervention: 1540 nm fractional laser treatments (three monthly treatments)
Number of subjects: 17
Study 19291747 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 17
Study 16904063 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy package for generalized anxiety disorder (GAD)
Number of subjects: 18
Study 16904063 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment condition
Number of subjects: 18
Study 15534640 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based communication system
Number of subjects: 200
Study 15534640 — intervention group
Group type: COMPARATOR
Intervention: Traditional inquiries (visits, telephones)
Number of subjects: 200
Study 15151713 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of human menopausal gonadotrophin (HMG) by 75 IU on the day of antagonist administration (Group B)
Number of subjects: 151
Study 15151713 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of human menopausal gonadotrophin (HMG) (Group A)
Number of subjects: 151
Study 10654498 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin‐coated circuit with silicone‐coated oxygenator (Group A)
Number of subjects: 32
Study 10654498 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole heparin‐coated circuit (Group B)
Number of subjects: 32
Study 10654498 — intervention group
Group type: COMPARATOR
Intervention: Whole untreated circuit (Group C)
Number of subjects: 32
Study 9439154 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1N hydrochloric acid
Number of subjects: 12
Study 9439154 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 12
Study 8161673 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐ELS 4 L plus simethicone 120 mg
Number of subjects: 115
Study 8161673 — intervention group
Group type: COMPARATOR
Intervention: PEG‐ELS 4 L plus placebo
Number of subjects: 115
Study 2868339 — intervention group
Group type: EXPERIMENTAL
Intervention: UKALL VIII treatment regimen including continuous therapy during induction, long course of intramuscular asparaginase over 3 weeks, full-dose mercaptopurine and co-trimoxazole during CNS prophylaxis, sustained maximum tolerated doses of mercaptopurine and methotrexate maintenance.
Number of subjects: 1470
Study 2868339 — intervention group
Group type: EXPERIMENTAL
Intervention: UKALL VII treatment regimen for good-prognosis patients.
Number of subjects: 1470
Study 2868339 — intervention group
Group type: COMPARATOR
Intervention: Previous UKALL trials (UKALL II to VI).
Number of subjects: 1470
Study 2582828 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-spacer (0.36 mg of albuterol)
Number of subjects: 20
Study 2582828 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer (2.5 mg of albuterol)
Number of subjects: 20
Study 2582828 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-spacer
Number of subjects: 20
Study 2582828 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer
Number of subjects: 20
Study 30848846 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal sacrospinous fixation (VSF)
Number of subjects: 71
Study 30848846 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal sacrocolpopexy (ASC)
Number of subjects: 71
Study 30848846 — intervention group
Group type: COMPARATOR
Intervention: Both VSF and ASC
Number of subjects: 71
Study 27939230 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein cholesterol (LDL-C) variability
Number of subjects: 8658
Study 27939230 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (BP) variability
Number of subjects: 8658
Study 27939230 — intervention group
Group type: COMPARATOR
Intervention: High variability for both LDL-C and systolic BP
Number of subjects: 8658
Study 25885341 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice nurses (PNs) involvement in chlamydia testing
Number of subjects: 44
Study 25885341 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice nurses (PNs) involvement in partner notification
Number of subjects: 44
Study 23017611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary resuscitation (CPR)
Number of subjects: 196
Study 23017611 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation (MV)
Number of subjects: 196
Study 23017611 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoiding life-sustaining therapies
Number of subjects: 196
Study 23017611 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician error
Number of subjects: 196
Study 21419769 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic trimodal imaging (ETMI)
Number of subjects: 234
Study 21419769 — intervention group
Group type: COMPARATOR
Intervention: Standard video endoscopy (SVE)
Number of subjects: 234
Study 21419769 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 234
Study 21419769 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging (AFI)
Number of subjects: 234
Study 20137285 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IMA concentration in DR patients
Number of subjects: 234
Study 20137285 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hs-CRP concentration in DR patients
Number of subjects: 234
Study 20137285 — intervention group
Group type: COMPARATOR
Intervention: Serum IMA concentration in NDR patients
Number of subjects: 234
Study 20137285 — intervention group
Group type: COMPARATOR
Intervention: Serum hs-CRP concentration in NDR patients
Number of subjects: 234
Study 20137285 — intervention group
Group type: COMPARATOR
Intervention: Serum IMA concentration in controls
Number of subjects: 234
Study 20137285 — intervention group
Group type: COMPARATOR
Intervention: Serum hs-CRP concentration in controls
Number of subjects: 234
Study 20137285 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IMA concentration in PDR patients
Number of subjects: 234
Study 20137285 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hs-CRP concentration in PDR patients
Number of subjects: 234
Study 20137285 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IMA concentration in NPDR patients
Number of subjects: 234
Study 20137285 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hs-CRP concentration in NPDR patients
Number of subjects: 234
Study 17366340 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected posture for drivers
Number of subjects: 154
Study 17366340 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected posture for front passengers
Number of subjects: 154
Study 17366340 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected posture for rear passengers
Number of subjects: 154
Study 17366340 — intervention group
Group type: COMPARATOR
Intervention: Sagging posture
Number of subjects: 154
Study 17366340 — intervention group
Group type: COMPARATOR
Intervention: Age factor
Number of subjects: 154
Study 14964743 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluorouracil cream (0.5% 5-fluorouracil in a microsphere vehicle)
Number of subjects: 0
Study 11434159 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Peritoneal Dialysis (APD)
Number of subjects: 52
Study 11434159 — intervention group
Group type: COMPARATOR
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 52
Study 11434159 — intervention group
Group type: EXPERIMENTAL
Intervention: APD
Number of subjects: 52
Study 11434159 — intervention group
Group type: COMPARATOR
Intervention: CAPD
Number of subjects: 52
Study 9593407 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (surgery)
Number of subjects: 3024
Study 9593407 — intervention group
Group type: COMPARATOR
Intervention: Control (surgery to be avoided for as long as possible)
Number of subjects: 3024
Study 8017343 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B-6 supplementation
Number of subjects: 20
Study 8017343 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 20
Study 2687008 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol controlled-release (SCR) 4 mg
Number of subjects: 15
Study 2687008 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol controlled-release (SCR) 8 mg
Number of subjects: 15
Study 1103400 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily regimen of streptomycin, isoniazid, and pyrazinamide
Number of subjects: 211
Study 1103400 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 times weekly regimen of streptomycin, isoniazid, and pyrazinamide
Number of subjects: 211
Study 1103400 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly regimen of streptomycin, isoniazid, and pyrazinamide
Number of subjects: 211
Study 1103400 — intervention group
Group type: COMPARATOR
Intervention: Overall relapse rates after 6 months' chemotherapy
Number of subjects: 211
Study 1103400 — intervention group
Group type: COMPARATOR
Intervention: Overall relapse rates after 9 months' chemotherapy
Number of subjects: 211
Study 31169772 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-school older partners
Number of subjects: 1034
Study 31169772 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymous out-of-school peer partners
Number of subjects: 1034
Study 31169772 — intervention group
Group type: COMPARATOR
Intervention: Monogamous HIV-negative peer partners
Number of subjects: 1034
Study 31169772 — intervention group
Group type: COMPARATOR
Intervention: Prespecified partner types
Number of subjects: 1034
Study 28643323 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intensified protocol of six cycles of CHOP-14 with dose-dense rituximab and high-dose methotrexate
Number of subjects: 63
Study 28643323 — intervention group
Group type: COMPARATOR
Intervention: Four cycles R-CHOP-21 followed by first-line high-dose chemotherapy with autologous stem-cell support (HDCT-ASCT)
Number of subjects: 63
Study 28643323 — intervention group
Group type: COMPARATOR
Intervention: Cohort 2 (early intensified protocol) vs. Cohort 1 (R-CHOP-21)
Number of subjects: 63
Study 28643323 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2 (early intensified protocol)
Number of subjects: 63
Study 25758273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin treatment
Number of subjects: 2998
Study 23492914 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study 23492914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20689320 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K₂ (menatetrenone) 45 mg/day for 1 year
Number of subjects: 40
Study 20689320 — intervention group
Group type: COMPARATOR
Intervention: Control group without vitamin K₂
Number of subjects: 40
Study 19938906 — intervention group
Group type: EXPERIMENTAL
Intervention: Seliciclib (CYC202, R-roscovitine)
Number of subjects: 0
Study 17084786 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) style
Number of subjects: 46
Study 17084786 — intervention group
Group type: EXPERIMENTAL
Intervention: Confrontation
Number of subjects: 46
Study 17084786 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment condition, session sequence, and session date
Number of subjects: 46
Study 15643481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (SH) injection (2 ml, Hyalgan, 20 mg/2 ml; once a week for 5 weeks)
Number of subjects: 27
Study 15643481 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate solution (once a week for 3 weeks)
Number of subjects: 27
Study 15643481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (SH) injection
Number of subjects: 27
Study 11216739 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG without CPB (n = 40)
Number of subjects: 80
Study 11216739 — intervention group
Group type: COMPARATOR
Intervention: CABG with CPB (n = 40)
Number of subjects: 80
Study 9807848 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) insertion
Number of subjects: 48
Study 9807848 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT) intubation
Number of subjects: 48
Study 7799105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 31
Study 7799105 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 31
Study 2971582 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide/2% miconazole cream (BPO-MCZ)
Number of subjects: 52
Study 2971582 — intervention group
Group type: COMPARATOR
Intervention: 5% benzoyl peroxide gel (BPO)
Number of subjects: 52
Study 30664844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab every 4 weeks (Rq4)
Number of subjects: 747
Study 30664844 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4)
Number of subjects: 747
Study 30664844 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 8 weeks (2q8)
Number of subjects: 747
Study 30664844 — intervention group
Group type: EXPERIMENTAL
Intervention: IAI 2 mg every 4 weeks (2q4)
Number of subjects: 747
Study 25846350 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention for 1 year
Number of subjects: 300
Study 25846350 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study 24373674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascope‐Trainer (group A)
Number of subjects: 64
Study 24373674 — intervention group
Group type: COMPARATOR
Intervention: Classic fiberscope (group C)
Number of subjects: 64
Study 24373674 — intervention group
Group type: COMPARATOR
Intervention: Both groups A and C
Number of subjects: 64
Study 24373674 — intervention group
Group type: COMPARATOR
Intervention: Standard fiberscope (T1)
Number of subjects: 64
Study 23208967 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dexketoprofen 30 minutes prior to the operation (group 50/0)
Number of subjects: 100
Study 23208967 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dexketoprofen 30 minutes after the operation (group 0/50)
Number of subjects: 100
Study 23208967 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dexketoprofen both 30 minutes prior and 30 minutes after the operation (group 25/25)
Number of subjects: 100
Study 23208967 — intervention group
Group type: COMPARATOR
Intervention: No dexketoprofen (control group C)
Number of subjects: 100
Study 19997572 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy for four weeks
Number of subjects: 16
Study 19997572 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 controls without OSA)
Number of subjects: 16
Study 17502332 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 18
Study 17502332 — intervention group
Group type: COMPARATOR
Intervention: Active Cranking (AC)
Number of subjects: 18
Study 17502332 — intervention group
Group type: COMPARATOR
Intervention: Ventilatory Recovery (VR)
Number of subjects: 18
Study 15310735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal group (CR) consuming ready-to-eat cereal with low-fat milk 90 minutes after their evening meal for 4 weeks
Number of subjects: 0
Study 15310735 — intervention group
Group type: COMPARATOR
Intervention: No-cereal group (NC) continuing regular diet ad libitum
Number of subjects: 0
Study 11532204 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour course teaching computer use for evidence searching (1997-1998)
Number of subjects: 0
Study 11532204 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5-hour course teaching SUMSearch use (1999-2000)
Number of subjects: 0
Study 11532204 — intervention group
Group type: COMPARATOR
Intervention: Control group (students who did not receive the intervention)
Number of subjects: 0